Zunsemetinib is under clinical development by Aclaris Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Zunsemetinib’s likelihood of approval (LoA) and phase transition for Rheumatoid Arthritis took place on 28 May 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Zunsemetinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Zunsemetinib overview

Zunsemetinib (ATI-450, CDD-450) is under development for the treatment of pyoderma gangrenosum, chronic inflammation, psoriasis, psoriatic arthritis, inflammatory bowel disease, crohn's colitis, rheumatoid arthritis, and hidradenitis suppurativa and, metastatic breast cancer and chemotherapy-induced bone loss, pancreatic cancer and gout. It is administered through oral route. The drug candidate targets MAP2K2 which regulates MK2-PI pathway. The drug candidate is developed based on KINect platform technology which works by identifying protein kinase inhibiting drugs using structure based drug design.

The drug candidate was also under development for the treatment of neutrophilic dermatosis, Cryopyrin-associated periodic syndromes like familial cold autoinflammatory syndrome, muckle-wells syndrome, or neonatal onset multisystem inflammatory disease.

Aclaris Therapeutics overview

Aclaris Therapeutics is bio-pharmaceutical company focused on identifying, developing and commercializing small molecule therapies for immuno-inflammatory conditions. Its lead product, ESKATA is a proprietary formulation of high-concentration hydrogen peroxide topical solution prescribed for the treatment of raised seborrheic keratosis (SK). The company’s pipeline products include A-101, ATI-1777-oral JAK 1/3 inhibitor, ATI-501, ATI-450-oral MK2 pathway inhibitor, soft JAK inhibitor, ITK oral anti-IL17 and ITK topical anti-IL17.Aclaris Therapeutics’ pipeline products are used for the treatment of common warts, alopecia areata, androgenetic alopecia, psoriasis, arthritis, gangrenosum, inflammatory bowel disease and atopic dermatitis. The company also develops investigational drugs to treat skin and hair conditions. Aclaris Therapeutics is headquartered in Wayne, Pennsylvania, the US.

Quick View Zunsemetinib LOA Data

Report Segments
  • Innovator
Drug Name
  • Zunsemetinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Genetic Disorders
  • Immunology
  • Infectious Disease
  • Musculoskeletal Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.